Hemophilia
📧 Sign up to get email alerts when something new happens for Hemophilia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: Long-term Anticoagulation in a Patient With Severe Hemophilia A
This clinical trial update indicates that recruitment is ongoing for a study examining long-term anticoagulation in patients with severe Hem…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors [Phase 3]
Phase 3 trial evaluating concizumab for Hemophilia A and Hemophilia B with or without inhibitors; the study is currently active but not recr…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
A clinical trial update indicating ongoing enrollment by invitation for males with Hemophilia A being treated prophylactically with Esperoct…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
This clinical trial update describes a study following males with hemophilia B who are on prophylaxis with Refixia or REBINYN, with enrollme…
-
EMA approval · 2025-12-19EMA Authorised: Altuvoct (Efanesoctocog alfa) — Swedish Orphan Biovitrum AB (publ)
The EMA authorised Altuvoct (efanesoctocog alfa) for Hemophilia A, with orphan medicine designation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX [Phase 3]
An update on the ongoing Phase 3 long-term safety and efficacy study of fitusiran in patients with Hemophilia A or B, including those with i…
-
EMA approval · 2025-12-11EMA Authorised: Afstyla (lonoctocog alfa) — CSL Behring GmbH
Afstyla (lonoctocog alfa) by CSL Behring GmbH has been authorised in the EU for the treatment of Hemophilia A.
-
EMA approval · 2025-12-10EMA Authorised: Kovaltry (octocog alfa) — Bayer AG
The EMA authorised Kovaltry (octocog alfa) from Bayer AG for the treatment of Hemophilia A. Decision date: 13 August 2025.
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A [Phase 3]
A Phase 3 clinical trial evaluating GS1191-0445 Injection for the treatment of Hemophilia A, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors [Phase 3]
A Phase 3 study evaluating Mim8 in adults and adolescents with Hemophilia A, with or without inhibitors, has completed.
-
EMA approval · 2025-12-05EMA Authorised: Adynovi (rurioctocog alfa pegol) — Baxalta Innovations GmbH
The European Medicines Agency authorized Adynovi (rurioctocog alfa pegol) from Baxalta Innovations GmbH for use in Hemophilia A.
-
EMA approval · 2025-12-04EMA Authorised: Jivi (Damoctocog alfa pegol) — Bayer AG
The European Medicines Agency has authorised Bayer's Jivi (damoctocog alfa pegol) for the treatment of Hemophilia A in the EU.
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Feasibility and Safety of Blood-Flow-Restriction Training in Patients With Hemophilia [NA]
A clinical trial is evaluating the feasibility and safety of blood-flow-restriction training in patients with hemophilia; the study is curre…
-
EMA approval · 2025-11-25EMA Authorised: Refixia (nonacog beta pegol) — Novo Nordisk A/S
The European Medicines Agency authorised Refixia, a nonacog beta pegol product from Novo Nordisk A/S, for the treatment of Hemophilia B.
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient [Phase 1]
A Phase 1b trial evaluated MG1113 in hemophilia patients to assess safety, tolerability, pharmacokinetics and pharmacodynamics. The study ha…
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: Balance Evaluation in Adult Hemophilia
A completed clinical trial evaluating balance and postural control in adults with hemophilia.
-
EMA approval · 2025-11-21EMA Authorised: Obizur (susoctocog alfa) — Baxalta Innovations GmbH
The European Medicines Agency authorised Obizur (susoctocog alfa) from Baxalta Innovations GmbH for the treatment of Hemophilia A.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B [Phase 3]
Biocad's ANB-002 is being studied in a Phase 3 open-label, single-dose trial in patients with Hemophilia B. The study is currently recruitin…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy [Phase 4]
A Phase 4 clinical trial evaluating efanesoctocog alfa for prophylaxis in Hemophilia A patients with synovial hypertrophy is currently recru…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: MRI Role in Knee Hemophilic Arthopathy
A study from Assiut University is evaluating the role of MRI in knee hemophilic arthropathy and is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy
This document reports a completed clinical trial that assesses the knowledge, beliefs, and attitudes of patients with Hemophilia B toward ge…
-
CLINICAL_TRIALS trial_result · 2025-11-13Clinical Trial Update: A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors [Phase 3]
Phase 3 trial evaluating Mim8 in children with Hemophilia A, with or without inhibitors, has completed.
-
CLINICAL_TRIALS research · 2025-11-13Clinical Trial Update: Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A [Phase 1]
A Phase 1 gene therapy trial aims to produce Factor VIII in platelets to treat Hemophilia A; the study status is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Prophylaxis Regimen for Hemophilia A Patients [Phase 4]
Bayer reports completed Phase 4 results for a prophylaxis regimen in patients with Hemophilia A.
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) [Phase 3]
Phase 3 trial evaluating the efficacy and safety of FIX prophylaxis for adult Hemophilia B and FVIII prophylaxis for adult Hemophilia A; the…